Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIV(mac251) Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial

The recombinant canarypox vector, ALVAC-HIV, together with human immunodeficiency virus (HIV) gp120 envelope glycoprotein, has protected 31.2% of Thai individuals from HIV acquisition in the RV144 HIV vaccine trial. This outcome was unexpected, given the limited ability of the vaccine components to...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Pegu, Poonam, Vaccari, Monica, Gordon, Shari, Keele, Brandon F., Doster, Melvin, Guan, Yongjun, Ferrari, Guido, Pal, Ranajit, Ferrari, Maria Grazia, Whitney, Stephen, Hudacik, Lauren, Billings, Erik, Rao, Mangala, Montefiori, David, Tomaras, Georgia, Alam, S. Munir, Fenizia, Claudio, Lifson, Jeffrey D., Stablein, Donald, Tartaglia, Jim, Michael, Nelson, Kim, Jerome, Venzon, David, Franchini, Genoveffa
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology 2013
Materias:
Vaccines and Antiviral Agents
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3554145/
https://ncbi.nlm.nih.gov/pubmed/23175374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.02544-12
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares